{"groups":[{"description":"Induction phase: Patients who enrolled received induction doses of CT-P13 5mg/kg via intravenous (IV) infusion at Weeks 0, 2, and 6.","id":"FG000","title":"CT-P13 IV 5mg/kg"},{"description":"Maintenance phase: Patients who were classified as CDAI-100 responder at Week 10 received CT-P13 120 mg subcutaneously every 2 weeks from Week 10 to Week 54.\n\nFrom Week 22, patients who initially responded but then lost response could increase the dose to CT-P13 SC 240 mg (double injection \\[2 shots\\] of CT-P13 SC 120 mg) every 2 weeks.","id":"FG001","title":"CT-P13 SC 120 mg"},{"description":"Maintenance phase: Patients who were classified as CDAI-100 responder at Week 10 received placebo-matching subcutaneously every 2 weeks from Week 10 to Week 54.\n\nFrom Week 22, patients who initially responded but then lost response could increase the dose to CT-P13 SC 240 mg (double injection \\[2 shots\\] of CT-P13 SC 120 mg) every 2 weeks.","id":"FG002","title":"Placebo"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"396"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"343"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"53"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Induction Phase"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"231"},{"groupId":"FG002","numSubjects":"112"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"196"},{"groupId":"FG002","numSubjects":"87"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"35"},{"groupId":"FG002","numSubjects":"25"}],"type":"NOT COMPLETED"}],"title":"Maintenance Phase"}]}